Double-Punch before surgery: can combo therapy keep liver cancer from coming back?
NCT ID NCT07352007
Summary
This study is testing if a new pre-surgery treatment can better control liver cancer and prevent it from returning. It will compare two approaches in 110 patients with operable liver cancer. One group gets a combination of immunotherapy (sintilimab) and targeted radiation before surgery, while the other group has surgery first. Both groups receive follow-up immunotherapy for up to a year after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ShandongShandong Cancer Hospital and Institute
Jinan, Shandong, China
Conditions
Explore the condition pages connected to this study.